MECHANISM(S) OF ACTION OF NERVE GROWTH FACTOR
MECHANISM(S) OF ACTION OF NERVE GROWTH FACTOR
批准号:
3407226
负责人:
DAVID L SIMPSON
金额:
$9.04万
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-08-01 至 1987-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The importance of nerve growth factor (NGF) in the development and
maintenance of the nervous system is well documented. While much is known
about its chemistry and structure and about the biological processes in
which NGF participates, little progress has been made toward understanding
the mechanism(s) by which NGF acts. The overall objective of this proposal
is to investigate two major questions in hormone-receptor biochemistry with
respect to NGF: (I) is the internalization and subsequent processing of an
NGF-receptor complex necessary for elicitation of the physiological
responses to this hormone (i.e., NGF)? and (II) can a hormone, in this case
NGF, exert its physiological responses if it is introduced into a target
cell by a mechanism which by-passes its native receptor (the NGF
receptor)? The experimental approach will take advantage of "chimeric
toxin technology", a new and powerful methodology, which will be used in
this project for the selection of cell variants with altered NGF-receptor
functions. A rat pheochromocytoma-derived clonal cell line, PC-12, which
responds to NGF by extensive neurite outgrowth and acquisition of
neuron-like differentiated properties will be used as a tissue culture
model system for these studies. To answer the first question, a "chimeric"
or hybrid conjugate consisting of NGF and purified, highly-toxic ricin A
chain will be constructed. This receptor-specific conjugate (NGF-A) will
be used to select variant PC-12 lines (clones) which are resistant to
killing by toxin. Two resulting variant phenotypes, NGF-receptor negative
(R-) and NGF-receptor positive-internalization negative (R+I-), will be
distinguished by standard receptor-binding assays.
Internalization-negative variants (R+I-) will then be tested to determine
if NGF binding alone is sufficient to elicit responses to NGF. To answer
the second question, a "chimeric" conjugate (NGF-B) consisting of NGF and
the purified B chain of ricin, the non-toxic galactose-binding subunit will
be constructed, and used to introduce NGF into (R-) cells via ricin
receptors. The NGF-B conjugate will then be tested on the
receptor-negative variants (R-). These clones will be used to directly
test for the importance of the NGF-receptor in cellular responsiveness to
NGF, by assaying for NGF-dependent phenomena such as neurite outgrowth and
known pleiotypic responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金